换肤

悦康药业

i问董秘

A03955

主营介绍

  • 主营业务：

    以原料药和制剂研发、生产与销售

  • 产品类型：

    药物、消化系统药物、糖尿病药物、抗感染药物

  • 产品名称：

    药物 、 消化系统药物 、 糖尿病药物 、 抗感染药物

  • 经营范围：

    生产粉针剂(头孢菌素类、青霉素类)、冻干粉针剂(含抗肿瘤类)、小容量注射剂(含抗肿瘤类)、片剂(含头孢菌素类)、硬胶囊剂(含头孢菌素类、青霉素类)、颗粒剂(含头孢菌素类、青霉素类)、散剂、栓剂(含激素类)、软膏剂、乳膏剂(含激素类)、凝胶剂、干混悬剂(头孢菌素类)、药用辅料(药品生产许可证有效期至2020年12月15日)；生产具有HDPE隔离干燥功能的药品包装瓶；货物专用运输(冷藏保鲜)(道路运输经营许可证有效期至2022年12月24日)；医药产品的技术开发；货物进出口、技术进出口、代理进出口；销售(不含零售)化工产品(不含危险化学品及一类易制毒化学品)。(企业依法自主选择经营项目，开展经营活动；货物专用运输(冷藏保鲜)以及依法须经批准的项目，经相关部门批准后依批准的内容开展经营活动；不得从事本市产业政策禁止和限制类项目的经营活动。)

主营构成分析

报告期
报告期
{"2020-06-30":{"YYSR":{"2":[["\u5fc3\u8111\u8840\u7ba1\u7c7b","68444.02"],["\u6297\u611f\u67d3","53659.87"],["\u6d88\u5316\u7cfb\u7edf\u7c7b","21511.69"],["\u964d\u7cd6\u7c7b","8735.10"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",15807.73]],"3":[["\u5185\u9500","158686.21"],["\u5916\u9500","3415.99"]]},"YYCB":{"2":[["\u5fc3\u8111\u8840\u7ba1\u7c7b","5039.33"],["\u6297\u611f\u67d3","31706.77"],["\u6d88\u5316\u7cfb\u7edf\u7c7b","9603.87"],["\u964d\u7cd6\u7c7b","3961.25"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",11812.97]],"3":[["\u5185\u9500","55398.72"],["\u5916\u9500","2880.27"]]},"LRBL":{"2":[["\u5fc3\u8111\u8840\u7ba1\u7c7b","59.80"],["\u6297\u611f\u67d3","20.70"],["\u6d88\u5316\u7cfb\u7edf\u7c7b","11.23"],["\u964d\u7cd6\u7c7b","4.50"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",3.77]],"3":[["\u5185\u9500","99.48"],["\u5916\u9500","0.52"]]}},"2019-12-31":{"YYSR":{"2":[["\u6297\u611f\u67d3","168628.98"],["\u5fc3\u8111\u8840\u7ba1\u7c7b","155773.03"],["\u6d88\u5316\u7cfb\u7edf\u7c7b","60316.96"],["\u964d\u7cd6\u7c7b","14505.89"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",29533.14]],"3":[["\u5185\u9500","410830.42"],["\u5916\u9500","4748.39"]]},"YYCB":{"2":[["\u6297\u611f\u67d3","105960.64"],["\u5fc3\u8111\u8840\u7ba1\u7c7b","11688.42"],["\u6d88\u5316\u7cfb\u7edf\u7c7b","20838.79"],["\u964d\u7cd6\u7c7b","5551.14"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",23523.99]],"3":[["\u5185\u9500","154194.64"],["\u5916\u9500","4341.81"]]},"LRBL":{"2":[["\u6297\u611f\u67d3","23.99"],["\u5fc3\u8111\u8840\u7ba1\u7c7b","55.16"],["\u6d88\u5316\u7cfb\u7edf\u7c7b","15.11"],["\u964d\u7cd6\u7c7b","3.43"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",2.29]],"3":[["\u5185\u9500","99.84"],["\u5916\u9500","0.16"]]}},"2018-12-31":{"YYSR":{"2":[["\u6297\u611f\u67d3","156750.03"],["\u5fc3\u8111\u8840\u7ba1\u7c7b","137205.55"],["\u6d88\u5316\u7cfb\u7edf\u7c7b","54239.68"],["\u964d\u7cd6\u7c7b","26026.96"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",24048.02]],"3":[["\u5185\u9500","387028.54"],["\u5916\u9500","3039.08"]]},"YYCB":{"2":[["\u6297\u611f\u67d3","99840.46"],["\u5fc3\u8111\u8840\u7ba1\u7c7b","9269.81"],["\u6d88\u5316\u7cfb\u7edf\u7c7b","18524.63"],["\u964d\u7cd6\u7c7b","11510.46"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",19415.43]],"3":[["\u5185\u9500","149572.81"],["\u5916\u9500","2871.93"]]},"LRBL":{"2":[["\u6297\u611f\u67d3","23.74"],["\u5fc3\u8111\u8840\u7ba1\u7c7b","53.37"],["\u6d88\u5316\u7cfb\u7edf\u7c7b","14.90"],["\u964d\u7cd6\u7c7b","6.06"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",1.93]],"3":[["\u5185\u9500","99.93"],["\u5916\u9500","0.07"]]}}}
{"YYSR":{"chartWrap2":[{"name":"\u5fc3\u8111\u8840\u7ba1\u7c7b","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[68444.02,155773.03,137205.55],"columnData":[40.7,36.33,34.45],"unit":["6.84\u4ebf","15.58\u4ebf","13.72\u4ebf"]},{"name":"\u6297\u611f\u67d3","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[53659.87,168628.98,156750.03],"columnData":[31.91,39.33,39.36],"unit":["5.37\u4ebf","16.86\u4ebf","15.68\u4ebf"]},{"name":"\u6d88\u5316\u7cfb\u7edf\u7c7b","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[21511.69,60316.96,54239.68],"columnData":[12.79,14.07,13.62],"unit":["2.15\u4ebf","6.03\u4ebf","5.42\u4ebf"]},{"name":"\u964d\u7cd6\u7c7b","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[8735.1,14505.89,26026.96],"columnData":[5.19,3.38,6.53],"unit":["8735.10\u4e07","1.45\u4ebf","2.60\u4ebf"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[15807.73,29533.14,24048.02],"columnData":[9.4,6.88,6.04],"unit":["1.58\u4ebf","2.95\u4ebf","2.40\u4ebf"]}],"chartWrap3":[{"name":"\u5185\u9500","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[158686.21,410830.42,387028.54],"columnData":[97.89,98.86,99.22],"unit":["15.87\u4ebf","41.08\u4ebf","38.70\u4ebf"]},{"name":"\u5916\u9500","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[3415.99,4748.39,3039.08],"columnData":[2.11,1.14,0.78],"unit":["3415.99\u4e07","4748.39\u4e07","3039.08\u4e07"]}]},"YYCB":{"chartWrap2":[{"name":"\u5fc3\u8111\u8840\u7ba1\u7c7b","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[5039.33,11688.42,9269.81],"columnData":[8.11,6.98,5.85],"unit":["5039.33\u4e07","1.17\u4ebf","9269.81\u4e07"]},{"name":"\u6297\u611f\u67d3","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[31706.77,105960.64,99840.46],"columnData":[51.04,63.24,62.97],"unit":["3.17\u4ebf","10.60\u4ebf","9.98\u4ebf"]},{"name":"\u6d88\u5316\u7cfb\u7edf\u7c7b","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[9603.87,20838.79,18524.63],"columnData":[15.46,12.44,11.68],"unit":["9603.87\u4e07","2.08\u4ebf","1.85\u4ebf"]},{"name":"\u964d\u7cd6\u7c7b","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[3961.25,5551.14,11510.46],"columnData":[6.38,3.31,7.26],"unit":["3961.25\u4e07","5551.14\u4e07","1.15\u4ebf"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[11812.97,23523.99,19415.43],"columnData":[19.01,14.04,12.24],"unit":["1.18\u4ebf","2.35\u4ebf","1.94\u4ebf"]}],"chartWrap3":[{"name":"\u5185\u9500","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[55398.72,154194.64,149572.81],"columnData":[95.06,97.26,98.12],"unit":["5.54\u4ebf","15.42\u4ebf","14.96\u4ebf"]},{"name":"\u5916\u9500","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[2880.27,4341.81,2871.93],"columnData":[4.94,2.74,1.88],"unit":["2880.27\u4e07","4341.81\u4e07","2871.93\u4e07"]}]},"LRBL":{"chartWrap2":[{"name":"\u5fc3\u8111\u8840\u7ba1\u7c7b","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[59.8,55.16,53.37],"columnData":[59.8,55.16,53.37],"unit":["59.80\u4e07","55.16\u4e07","53.37\u4e07"]},{"name":"\u6297\u611f\u67d3","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[20.7,23.99,23.74],"columnData":[20.7,23.99,23.74],"unit":["20.70\u4e07","23.99\u4e07","23.74\u4e07"]},{"name":"\u6d88\u5316\u7cfb\u7edf\u7c7b","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[11.23,15.11,14.9],"columnData":[11.23,15.11,14.9],"unit":["11.23\u4e07","15.11\u4e07","14.90\u4e07"]},{"name":"\u964d\u7cd6\u7c7b","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[4.5,3.43,6.06],"columnData":[4.5,3.43,6.06],"unit":["4.50\u4e07","3.43\u4e07","6.06\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[3.77,2.29,1.93],"columnData":[3.77,2.29,1.93],"unit":["3.77\u4e07","2.29\u4e07","1.93\u4e07"]}],"chartWrap3":[{"name":"\u5185\u9500","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[99.48,99.84,99.93],"columnData":[99.48,99.84,99.93],"unit":["99.48\u4e07","99.84\u4e07","99.93\u4e07"]},{"name":"\u5916\u9500","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0.52,0.16,0.07],"columnData":[0.52,0.16,0.07],"unit":["5200.00","1600.00","700.00"]}]}}

营业收入 X

单位（%） 单位（万元）
注：通常在中报、年报时披露　
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按产品 心脑血管类 6.84亿 40.70% 5039.33万 8.11% 59.80% 92.64%
抗感染 5.37亿 31.91% 3.17亿 51.04% 20.70% 40.91%
消化系统类 2.15亿 12.79% 9603.87万 15.46% 11.23% 55.36%
降糖类 8735.10万 5.19% 3961.25万 6.38% 4.50% 54.65%
原料药 7444.11万 4.43% 6264.18万 10.08% 1.11% 15.85%
其他业务 6056.20万 3.60% 3845.22万 6.19% 2.09% 36.51%
其他 1587.37万 0.94% 1194.28万 1.92% 0.37% 24.76%
技术服务 720.05万 0.43% 509.29万 0.82% 0.20% 29.27%
按地区 内销 15.87亿 97.89% 5.54亿 95.06% 99.48% 65.09%
外销 3415.99万 2.11% 2880.27万 4.94% 0.52% 15.68%

董事会经营评述

　　（一）营业收入构成及变动分析
　　1、营业收入总体分析
　　报告期内，公司营业收入呈增长趋势，2018年度较2017年度增幅较大，主要系“两票制”逐步实施提升了公司产品出厂价、公司产品逐步占领市场带来销量提升；2019年度收入较2018年度略有增长，主要系公司产品销量继续提升。
　　报告期内，公司主营业务收入占比较高，其他业务收入主要为抗生素原料药及包材贸易收入等。
　　2、主营业务收入按适应症领域构成分析
　　公司主营业务收入主要包括抗感染、心脑血管类、消化系统类、糖尿病类等制剂销售、原料药销售和技术服务等。原料药业务主要由公司子公司河南康达制药开展，伴随河南康达制药设备投产和市场打开，... 查看全部▼

　　（一）营业收入构成及变动分析
　　1、营业收入总体分析
　　报告期内，公司营业收入呈增长趋势，2018年度较2017年度增幅较大，主要系“两票制”逐步实施提升了公司产品出厂价、公司产品逐步占领市场带来销量提升；2019年度收入较2018年度略有增长，主要系公司产品销量继续提升。
　　报告期内，公司主营业务收入占比较高，其他业务收入主要为抗生素原料药及包材贸易收入等。
　　2、主营业务收入按适应症领域构成分析
　　公司主营业务收入主要包括抗感染、心脑血管类、消化系统类、糖尿病类等制剂销售、原料药销售和技术服务等。原料药业务主要由公司子公司河南康达制药开展，伴随河南康达制药设备投产和市场打开，原料药收入在报告期内逐年上升。技术服务主要由公司子公司悦康科创开展，悦康科创主要向悦康药业合并体系内公司和外部公司提供药品研发、中试前验证等服务。
　　3、主营业务收入按药品品种构成分析
　　报告期内，公司销售的主要药品品种包括心脑血管类的银杏叶提取物注射液和天麻注射液，消化系统类的注射用兰索拉唑和奥美拉唑肠溶胶囊，糖尿病类的盐酸二甲双胍缓释片，抗感染类的明可欣（代理）、注射用头孢呋辛钠和注射用头孢曲松钠等。公司产品线和治疗领域较为丰富，报告期内上述主要品种占主营收入比例分别为74.27%、78.98%和78.82%。
　　3、主营业务收入的季节性分析
　　报告期内各季度销售收入占比基本保持稳定，公司银杏叶提取物注射液、天麻素注射液等产品适用于心脑血管疾病，相关疾病在冬季属于相对高发期，产品需求量较高，加之春节备货等因素，公司收入在四季度相对较高。公司产品销售无明显季节性，各季度间分布基本稳定，不存在较大的季节性波动风险。
　　4、其他业务收入分析
　　公司其他业务收入包括抗生素原料药及包材贸易收入等。公司属于国内规模较大抗生素生产企业，公司采购部分抗生素原料药后，在满足自身生产需求的前提下，亦出售给同行业抗生素生产公司，出售价格略高于采购成本。包材贸易收入系公司子公司润泰商贸出售胶塞、铝盖等药用包装材料所产生的。 收起▲

同花顺个股页面 | F10论坛 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。